Association of body mass index with immune recovery, virological failure and cardiovascular disease risk among people living with HIV.
HIV
body mass index
cardiovascular risks
immune recovery
virological response
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
03
08
2020
revised:
13
10
2020
accepted:
21
10
2020
pubmed:
18
11
2020
medline:
15
3
2022
entrez:
17
11
2020
Statut:
ppublish
Résumé
We conducted a longitudinal cohort analysis to evaluate the association of pre-treatment body mass index (BMI) with CD4 recovery, virological failure (VF) and cardiovascular risk disease (CVD) markers among people living with HIV (PLHIV). Participants who were enrolled between January 2003 and March 2019 in a regional Asia HIV cohort with weight and height measurements prior to antiretroviral therapy (ART) initiation were included. Factors associated with mean CD4 increase were analysed using repeated-measures linear regression. Time to first VF after 6 months on ART and time to first development of CVD risk markers were analysed using Cox regression models. Sensitivity analyses were done adjusting for Asian BMI thresholds. Of 4993 PLHIV (66% male), 62% had pre-treatment BMI in the normal range (18.5-25.0 kg/m High pre-treatment BMI was associated with better immune reconstitution and CVD risk factor development in an Asian PLHIV cohort.
Identifiants
pubmed: 33200864
doi: 10.1111/hiv.13017
pmc: PMC8428815
mid: NIHMS1737933
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
294-306Subventions
Organisme : NIAID NIH HHS
ID : U01 AI069907
Pays : United States
Informations de copyright
© 2020 British HIV Association.
Références
Int J Obes (Lond). 2007 Aug;31(8):1232-9
pubmed: 17342075
Lancet HIV. 2017 Aug;4(8):e349-e356
pubmed: 28501495
Curr HIV/AIDS Rep. 2018 Feb;15(1):60-71
pubmed: 29423731
J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):228-36
pubmed: 27171741
PLoS One. 2019 Feb 5;14(2):e0211344
pubmed: 30721233
Med Princ Pract. 2013;22(1):54-8
pubmed: 22722316
Antivir Ther. 2016;21(6):517-527
pubmed: 26961354
AIDS. 2015 Mar 27;29(6):667-74
pubmed: 25849830
J Int AIDS Soc. 2019 Jan;22(1):e25236
pubmed: 30697944
AIDS. 2017 Jun 1;31 Suppl 2:S121-S128
pubmed: 28471942
J Infect Dis. 2019 Jul 2;220(3):420-431
pubmed: 30893434
Br J Nutr. 2009 Aug;102(4):632-41
pubmed: 19203416
Arthritis Res Ther. 2006;8(5):217
pubmed: 16879738
J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):e14-e21
pubmed: 29040163
HIV Med. 2016 Apr;17(4):255-68
pubmed: 26216031
J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):197-204
pubmed: 27116044
Exp Diabetes Res. 2012;2012:103063
pubmed: 22203832
J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):579-588
pubmed: 29771788
Br J Nutr. 2016 Jun;115(12):2114-21
pubmed: 27087233
Am J Infect Dis. 2006;2(3):141-152
pubmed: 17183414
BMC Infect Dis. 2019 May 2;19(1):373
pubmed: 31046702
J Infect Dis. 2013 Oct 15;208(8):1194-201
pubmed: 23878320
J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):507-13
pubmed: 19730111
AIDS Res Hum Retroviruses. 2016 Aug;32(8):772-81
pubmed: 27030657
HIV Clin Trials. 2011 Jul-Aug;12(4):222-7
pubmed: 22044858
HIV Med. 2015 Jan;16(1):67-72
pubmed: 25230709
Nat Rev Immunol. 2006 Oct;6(10):772-83
pubmed: 16998510
J Endocrinol. 2014 Jan 08;220(2):T47-59
pubmed: 24403378
AIDS. 2010 Apr 24;24(7):1069-72
pubmed: 20216300
Metabolism. 2009 Aug;58(8):1200-7
pubmed: 19428036
HIV Med. 2015 Oct;16(9):572-7
pubmed: 25960080
Nature. 1998 Aug 27;394(6696):897-901
pubmed: 9732873
Metabolism. 1997 Mar;46(3):303-5
pubmed: 9054474